Facility Details

Creative Biolabs has conducted extensive and in-depth research on the MERS epidemic in 2012, and has contributed a lot to the research and control of coronavirus pneumonia, and thus has accumulated a lot of experience. Therefore, at the end of 2019, when a new type of coronavirus pneumonia (which is officially named by the WHO as coronavirus disease 2019, abbreviated "COVID-19" on Feb 11, 2020) broke out in Wuhan, China, Creative Biolabs quickly organized relevant researchers, and set up a dedicated research team to carry out intensive analysis and research on the SARS-COV2 virus (formerly known as 2019-nCoV). The team has rapidly developed related proteins, antibodies, nucleic acid extraction kits and other products to help researchers quickly develop effective anti-COVID-19 drugs and vaccines. Relying on our mature drug development and vaccine development technology and experience, we also provide researchers with excellent CRO services regarding to discovery services of anti-SARS-COV2 (COVID-19, 2019-nCoV) drugs as well as vaccine development services, preclinical research services, various in vivo and in vivo research models, and in vivo diagnostic immunoassay services.

Comprehensive COVID-19/ SARS-COV2/ 2019-nCoV Research Tools and Services